The FDA’s approval of Fujirebio’s ‘Lumipulse G,’ a blood test with over 90% accuracy, can now be used by doctors to determine whether someone has a build-up of amyloid plaques in their brain.

A new blood test is being called a game changer for helping diagnose Alzheimer’s, and UNLV helped contribute research to it.

Dr. Ausim Azizi is among those seeing the overall early results, as Yale New Haven Hospital is in the forefront of research ...

The Lumipulse blood test is made by Japanese company, Fujirebio Diagnostics, which markets a similar Alzheimer's test that measures cerebrospinal fluid collected by spinal tap.

According to the FDA’s press release, the Lumipulse blood test works by measuring the amount of pTau 217 and beta-amyloid 1-42 in the plasma of the blood.

The first-ever blood test to detect Alzheimer’s disease has been cleared by the U.S. Food and Drug Administration (FDA). In a Friday press release, the agency announced its approval of the first ...

The Lumipulse blood test became the first “in vitro diagnostic device” to be endorsed by the U.S. Food and Drug Administration, which cleared it earlier this month as a new tool in diagnosing ...

The Lumipulse blood test became the first “in vitro diagnostic device” to be endorsed by the U.S. Food and Drug Administration, which cleared it earlier this month as a new tool in diagnosing ...

The Lumipulse blood test became the first “in vitro diagnostic device” to be endorsed by the U.S. Food and Drug Administration, which cleared it earlier this month as a new tool in diagnosing ...

The blood test is substantially equivalent to a Lumipulse CSF test. Fujirebio compared the blood test to PET scans and CSF results in a multi-center clinical study of 499 plasma samples from ...

The Food and Drug Administration (FDA) announced Friday it had cleared a new test to help diagnose adults with Alzheimer’s disease, the first diagnostic tool that uses a blood draw to check for ...

In a clinical study of 499 plasma samples from cognitively impaired adults, the Lumipulse test detected the presence of amyloid plaques in 91.7% of individuals.